Thursday, 5 November 2026European Markets

VAN DE VELDE And BARBARA BUI Have A High Dividend Yield And Return On Equity In The Apparel Manufacturing Industry.

Loading stream...

(vianews) - van de velde (van.br) is among this list of stock assets with the highest dividend rate and return on equity on the apparel manufacturing industry.

financial asset price forward dividend yield return on equity
van de velde (van.br) €32.55 6.88% 20.14%
barbara bui (bui.pa) €8.70 4.08% 125.51%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. van de velde (van.br)

6.88% forward dividend yield and 20.14% return on equity

van de velde nv, together with its subsidiaries, designs, develops, manufactures, and markets fashionable luxury lingerie and swimwear in europe and north america. the company operates through two segments, business to business and direct to consumer. it offers its products under the primadonna, marie jo, and sarda brand names. the company provides its products through its retail networks, website, and department stores, as well as independent retail and e-tail partners, franchisees, and marketplaces. van de velde nv was founded in 1919 and is headquartered in schellebelle, belgium. van de velde nv is a subsidiary of van de velde holding nv.

earnings per share

as for profitability, van de velde has a trailing twelve months eps of €2.61.

pe ratio

van de velde has a trailing twelve months price to earnings ratio of 12.47. meaning, the purchaser of the share is investing €12.47 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 20.14%.

volatility

van de velde's last week, last month's, and last quarter's current intraday variation average was a negative 2.52%, a negative 0.34%, and a positive 1.20%.

van de velde's highest amplitude of average volatility was 2.61% (last week), 0.97% (last month), and 1.20% (last quarter).

volume

today's last reported volume for van de velde is 8660 which is 0.39% below its average volume of 8694.

more news about van de velde.

2. barbara bui (bui.pa)

4.08% forward dividend yield and 125.51% return on equity

barbara bui sa engages in the manufacture, marketing, and sale of ready-to-wear clothing and accessories for women in france and internationally. the company offers coats, jackets, tops and shirts, t-shirts, mesh, pants, dresses and skirts, leather products, and tailored cloths; and accessories, such as shoes, bags, scarves, and belts. it offers its products through wholesale distributors, as well as online and offline stores. the company was incorporated in 1982 and is based in paris, france.

earnings per share

as for profitability, barbara bui has a trailing twelve months eps of €1.04.

pe ratio

barbara bui has a trailing twelve months price to earnings ratio of 8.37. meaning, the purchaser of the share is investing €8.37 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 125.51%.

more news about barbara bui.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com